Abstract
Osteoarthritis (OA) of the hand is highly prevalent in US senior citizens, developing in >50% of individuals aged >60 years. Hormonal, genetic and inflammatory mechanisms are known to increase the risk of hand OA and influence the course of the disease. However, the underlying processes in the development of hand OA are not well understood, and there is no known disease-modifying drug. Likewise, surgical interventions for affected hand joints have not proven as successful as joint replacement for the knee or hip. Current treatment of hand OA focuses on reducing pain and improving patient function to improve quality of life. Pharmacological approaches have included several oral therapies, such as paracetamol (acetaminophen), oral nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, all of which carry a risk of adverse events that typically increases with age. Topical NSAIDs, recently approved in the US, appear to provide efficacy similar to that of oral NSAIDs for hand OA, with less systemic NSAID exposure. Intraarticular corticosteroids and hyaluronic acid have also shown modest symptomatic efficacy with generally good tolerability. Two proposed disease-modifying therapies, chondroitin sulfate and hydroxychloroquine, have had unclear effects on disease modification in clinical trials. This review of pharmacotherapies for the treatment of hand OA focuses on their efficacy and safety in elderly patients. Articles cited herein were identified via a search of PubMed from January 2005 to November 2009. The bibliographies of articles identified through this search were searched manually for additional references of interest.
Similar content being viewed by others
References
Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998 May; 41(5): 778–99
Zhang Y, Niu J, Kelly-Hayes M, et al. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: the Framingham Study. Am J Epidemiol 2002 Dec 1; 156(11): 1021–7
Dahaghin S, Bierma-Zeinstra SM, Ginai AZ, et al. Prevalence and pattern of radiographic hand osteoarthritis and association with pain and disability (the Rotterdam study). Ann Rheum Dis 2005 May; 64(5): 682–7
Haara MM, Manninen P, Kröger H, et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis 2003; 62: 151–8
Wilder FV, Barrett JP, Farina EJ. Joint-specific prevalence of osteoarthritis of the hand. Osteoarthritis Cartilage 2006 Sep; 14(9): 953–7
Altman RD, Fries JF, Bloch DA, et al. Radiographic assessment of progression in osteoarthritis. Arthritis Rheum 1987 Nov; 30(11): 1214–25
Kjeken I, Dagfinrud H, Slatkowsky-Christensen B, et al. Activity limitations and participation restrictions in women with hand osteoarthritis: patients’ descriptions and associations between dimensions of functioning. Ann Rheum Dis 2005; 64(11): 1633–8
Solovieva S, Vehmas T, Riihimaki H, et al. Hand use and patterns of joint involvement in osteoarthritis: a comparison of female dentists and teachers. Rheumatology (Oxford) 2005 Apr; 44(4): 521–8
Cushnaghan J, Dieppe P. Study of 500 patients with limb joint osteoarthritis: I. Analysis by age, sex, and distribution of symptomatic joint sites. Ann Rheum Dis 1991 Jan; 50(1): 8–13
de Klerk BM, Schiphof D, Groeneveld FP, et al. No clear association between female hormonal aspects and osteoarthritis of the hand, hip and knee: a systematic review. Rheumatology (Oxford) 2009 Sep; 48(9): 1160–5
Spector TD, Nandra D, Hart DJ, et al. Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford Study. Ann Rheum Dis 1997 Jul; 56(7): 432–4
Zhang Y, McAlindon TE, Hannan MT, et al. Estrogen replacement therapy and worsening of radiographic knee osteoarthritis: the Framingham Study. Arthritis Rheum 1998 Oct; 41(10): 1867–73
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33
Botha-Scheepers SA, Watt I, Slagboom E, et al. Influence of familial factors on radiologic disease progression over two years in siblings with osteoarthritis at multiple sites: a prospective longitudinal cohort study. Arthritis Rheum 2007 May 15; 57(4): 626–32
Hirsch R, Lethbridge-Cejku M, Hanson R, et al. Familial aggregation of osteoarthritis: data from the Baltimore Longitudinal Study on Aging. Arthritis Rheum 1998 Jul; 41(7): 1227–32
Riyazi N, Meulenbelt I, Kroon HM, et al. Evidence for familial aggregation of hand, hip, and spine but not knee osteoarthritis in siblings with multiple joint involvement: the GARP study. Ann Rheum Dis 2005 Mar; 64(3): 438–43
MacGregor AJ, Li Q, Spector TD, et al. The genetic influence on radiographic osteoarthritis is site specific at the hand, hip and knee. Rheumatology (Oxford) 2009 Mar; 48(3): 277–80
Horton Jr WE, Lethbridge-Cejku M, Hochberg MC, et al. An association between an aggrecan polymorphic allele and bilateral hand osteoarthritis in elderly white men: data from the Baltimore Longitudinal Study of Aging (BLSA). Osteoarthritis Cartilage 1998 Jul; 6(4): 245–51
Kamarainen OP, Solovieva S, Vehmas T, et al. Aggrecan core protein of a certain length is protective against hand osteoarthritis. Osteoarthritis Cartilage 2006 Oct; 14(10): 1075–80
Kirk KM, Doege KJ, Hecht J, et al. Osteoarthritis of the hands, hips and knees in an Australian twin sample — evidence of association with the aggrecan VNTR polymorphism. Twin Res 2003 Feb; 6(1): 62–6
Carman WJ, Sowers M, Hawthorne VM, et al. Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study. Am J Epidemiol 1994 Jan 15; 139(2): 119–29
Cicuttini FM, Baker JR, Spector TD. The association of obesity with osteoarthritis of the hand and knee in women: a twin study. J Rheumatol 1996 Jul; 23(7): 1221–6
Oliveria SA, Felson DT, Cirillo PA, et al. Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology 1999 Mar; 10(2): 161–6
Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009; 121(6): 9–20
Singh G, Miller JD, Lee FH, et al. Prevalence of cardiovascular disease risk factors among US adults with self-reported osteoarthritis: data from the Third National Health and Nutrition Examination Survey. Am J Manag Care 2002 Oct; 8(15 Suppl.): S383–91
Jones G, Cooley HM, Bellamy N. A cross-sectional study of the association between Heberden’s nodes, radio-graphic osteoarthritis of the hands, grip strength, disability and pain. Osteoarthritis Cartilage 2001; 9: 606–11
Altman R, Alarcón G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990; 33: 1601–10
Zhang W, Doherty M, Leeb BF, et al. EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT. Ann Rheum Dis 2009 Jan; 68(1): 8–17
Ropes MW, Bennett GA, Cobb S, et al. 1958 revision of diagnostic criteria for rheumatoid arthritis. Arthritis Rheum 2008 Feb; 58(2 Suppl.): S15–9
Leeb BF, Sautner J, Andel I, et al. SACRAH: a score for assessment and quantification of chronic rheumatic affections of the hands. Rheumatology (Oxford) 2003 Oct; 42(10): 1173–8
Cheung PP, Dougados M, Gossec L. Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1,415 patients). Arthritis Care Res (Hoboken) 2010 Mar; 62(3): 323–34
Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006 Aug; 54(8): 2665–73
Chi ZC, Ma SZ. Rheumatologic manifestations of hepatic diseases. Hepatobiliary Pancreat Dis Int 2003 Feb; 2(1): 32–7
Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998 Jan; 41(1): 58–67
Tan AL, Grainger AJ, Tanner SF, et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum 2006 Apr; 54(4): 1328–33
Bravo CJ, Rizzo M, Hormel KB, et al. Pyrolytic carbon proximal interphalangeal joint arthroplasty: results with minimum two-year follow-up evaluation. J Hand Surg Am 2007 Jan; 32(1): 1–11
Field J. Two to five year follow-up of the LPM ceramic coated proximal interphalangeal joint arthroplasty. J Hand Surg Eur Vol 2008 Feb; 33(1): 38–44
Johnstone BR, Fitzgerald M, Smith KR, et al. Cemented versus uncemented surface replacement arthroplasty of the proximal interphalangeal joint with a mean 5-year follow-up. J Hand Surg Am 2008 May–Jun; 33(5): 726–32
Takigawa S, Meletiou S, Sauerbier M, et al. Long-term assessment of Swanson implant arthroplasty in the proximal interphalangeal joint of the hand. J Hand Surg Am 2004 Sep; 29(5): 785–95
Ethgen O, Bruyere O, Richy F, et al. Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. J Bone Joint Surg Am 2004 May; 86-A(5): 963–74
Virolainen P, Aro HT. High tibial osteotomy for the treatment of osteoarthritis of the knee: a review of the literature and a meta-analysis of follow-up studies. Arch Orthop Trauma Surg 2004 May; 124(4): 258–61
NICE. Osteoarthritis: the care and management of osteoarthritis in adults. London: National Collaborating Centre for Chronic Conditions, 2008 Feb. Report No.: NICE clinical guideline 59
Zhang W, Doherty M, Leeb BF, et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66(3): 377–88
Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 2005 Aug; 35 (1 Suppl. 1): 1–10
Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Dec 3; 331(7528): 1310–6
Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics — 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007 Feb 6; 115(5): e69–171
Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005 Jun 11; 330(7504): 1366
Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986 Mar; 80(3): 435–42
Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985 Apr; 33(4): 278–85
Rowe JW, Andres R, Tobin JD, et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976 Mar; 31(2): 155–63
Barkin RL, Buvanendran A. Focus on the COX-1 and COX-2 agents: renal events of nonsteroidal and antiinflammatory drugs-NSAIDs. Am J Ther 2004 Mar–Apr; 11(2): 124–9
Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs healthcare system: part I. Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005 Jan; 11(1): 5–15
Malhotra S, Karan RS, Pandhi P, et al. Drug related medical emergencies in the elderly: role of adverse drug reactions and non-compliance. Postgrad Med J 2001 Nov; 77(913): 703–7
Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging 2008; 25(4): 343–55
Bayliss EA, Ellis JL, Steiner JF. Barriers to self-management and quality-of-life outcomes in seniors with multi-morbidities. Ann Fam Med 2007 Sep–Oct; 5(5): 395–402
Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A metaanalysis of randomised controlled trials. Ann Rheum Dis 2004 Aug; 63(8): 901–7
Lee C, Straus WL, Balshaw R, et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 2004 Oct 15; 51(5): 746–54
American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009 Aug; 57(8): 1331–46
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16(2): 137–62
Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006; (1): CD004257
Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001 Sep; 12(5): 570–6
Henrich WL, Agodoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996 Jan; 27(1): 162–5
Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006 Jul 5; 296(1): 87–93
Larson AM, Polson J, Fontana RJ, et al., Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005 Dec; 42(6): 1364–72
National Collaborating Centre for Chronic Conditions. Osteoarthritis: the care and management of osteoarthritis in adults. London: Royal College of Physicians, 2008
Riess W, Schmid K, Botta L, et al. [The percutaneous absorption of diclofenac.] Arzneimittelforschung 1986 Jul; 36(7): 1092–6
Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1 % versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs 2010; 50: 50–61
Chou R, Helfand M, Peterson K, et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative Effectiveness Review No. 4. (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.) Rockville (MD): Agency for Healthcare Research and Quality, 2006 Sep [online]. Available from URL: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm [Accessed 2010 Aug 2]
Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain: systematic review and metaanalysis. BMC Musculoskelet Disord 2004 Aug 19; 5: 28
Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials [see comment]. J Rheumatol 2006 Mar; 33(3): 567–73
Altman RD, Dreiser RL, Fisher CL, et al. Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009 Sep; 36(9): 1991–9
Zacher J, Burger K, Farber L, et al. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden’s and/or Bouchard’s nodes): double-blind, controlled, randomized study. Aktuel Rheumatol 2001; 26: 7–14
McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992 Apr; 19(4): 604–7
Tubach F, Ravaud P, Baron G, et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 2005 Jan; 64(1): 29–33
Barthel HR, Peniston JH, Clark M, et al. Correlation of pain relief with physical function in hand osteoarthritis: a randomized controlled trial post hoc analysis. Arthritis Res Ther 2010; 12(1): R7
Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004 Apr 24; 328(7446): 991
Altman R, Barkin RL. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives. Postgrad Med 2009 Mar; 121(2): 139–47
Grifka JK, Zacher J, Brown JP, et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004; 22(5): 589–96
Seiler V. Meclofenamate sodium in the treatment of degenerative joint disease of the hand (Heberden nodes). Arzneimittelforschung 1983; 33(4A): 656–9
Dreiser RL, Gersberg M, Thomas F, et al. [Ibuprofen 800 mg in the treatment of arthrosis of the fingers or rhizarthrosis.] Rev Rhum Ed Fr 1993 Nov 30; 60(11): 836–41
Rovetta G, Monteforte P. Dexketoprofen-trometamol in patients with osteoarthritis of the hands. Minerva Ortoped Traumatol 2001; 52: 27–30
Lisse JR, Perlman M, Johansson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003 Oct 7; 139(7): 539–46
Fleischmann R, Tannenbaum H, Patel NP, et al. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis. BMC Musculoskelet Disord 2008; 9: 32
Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991 Nov 15; 115(10): 787–96
Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006 Jun 3; 332(7553): 1302–8
Franceschi M, Di Mario F, Leandro G, et al. Acid-related disorders in the elderly. Best Pract Res Clin Gastroenterol 2009; 23(6): 839–48
Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007 Aug; 15(8): 957–65
Joshi R. Intraarticular corticosteroid injection for first carpometacarpal osteoarthritis. J Rheumatol 2005 Jul; 32(7): 1305–6
Day CS, Gelberman R, Patel AA, et al. Basal joint osteoarthritis of the thumb: a prospective trial of steroid injection and splinting. J Hand Surg Am 2004 Mar; 29(2): 247–51
Salini V, De Amicis D, Abate M, et al. Ultrasound-guided hyaluronic acid injection in carpometacarpal osteoarthritis: short-term results. Int J Immunopathol Pharmacol 2009 Apr–Jun; 22(2): 455–60
Roux C, Fontas E, Breuil V, et al. Injection of intraarticular sodium hyaluronidate (Sinovial) into the carpometacarpal joint of the thumb (CMC 1) in osteoarthritis: a prospective evaluation of efficacy. Joint Bone Spine 2007 Jul; 74(4): 368–72
Schumacher HR, Meador R, Sieck M, et al. Pilot investigation of hyaluronate injections for first metacarpalcarpal (MC-C) osteoarthritis. J Clin Rheumatol 2004 Apr; 10(2): 59–62
Bahadir C, Onal B, Dayan VY, et al. Comparison of therapeutic effects of sodium hyaluronate and corticosteroid injections on trapeziometacarpal joint osteoarthritis. Clin Rheumatol 2009 May; 28(5): 529–33
Heyworth BE, Lee JH, Kim PD, et al. Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am 2008 Jan; 33(1): 40–8
Fuchs S, Monikes R, Wohlmeiner A, et al. Intra-articular hyaluronic acid compared with corticoid injections for the treatment of rhizarthrosis. Osteoarthritis Cartilage 2006 Jan; 14(1): 82–8
Stahl S, Karsh-Zafrir I, Ratzon N, et al. Comparison of intraarticular injection of depot corticosteroid and hyaluronic acid for treatment of degenerative trapeziometacarpal joints. J Clin Rheumatol 2005 Dec; 11(6): 299–302
Bannuru RR, Natov NS, Obadan IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009 Dec 15; 61(12): 1704–11
Lemont H, Hetman J. Cutaneous foot depigmentation following an intra-articular steroid injection. J Am Podiatr Med Assoc 1991 Nov; 81(11): 606–7
Dalinka MK, Stewart V, Bomalaski JS, et al. Periarticular calcifications in association with intra-articular corticosteroid injections. Radiology 1984 Dec; 153(3): 615–8
Gyuricza C, Umoh E, Wolfe SW. Multiple pulley rupture following corticosteroid injection for trigger digit: case report. J Hand Surg Am 2009 Oct; 34(8): 1444–8
So V, Pollard H. Management of Achilles tendon disorders: a case review. Australas Chiropr Osteopathy 1997 Jul; 6(2): 58–62
Smith AG, Kosygan K, Williams H, et al. Common extensor tendon rupture following corticosteroid injection for lateral tendinosis of the elbow. Br J Sports Med 1999 Dec; 33(6): 423–4; discussion 4–5
Haraldsson BT, Langberg H, Aagaard P, et al. Corticosteroids reduce the tensile strength of isolated collagen fascicles. Am J Sports Med 2006 Dec; 34(12): 1992–7
Rovetta G, Monteforte P, Molfetta G, et al. Chondroitin sulfate in erosive osteoarthritis of the hands. Int J Tissue React 2002; 24(1): 29–32
Rovetta G, Monteforte P, Molfetta G, et al. A two-year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Exp Clin Res 2004; 30(1): 11–6
Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol 2002 Jun; 21(3): 231–43
Punzi L, Bertazzolo N, Pianon M, et al. Soluble interleukin 2 receptors and treatment with hydroxychloroquine in erosive osteoarthritis. J Rheumatol 1996 Aug; 23(8): 1477–8
Fioravanti A, Fabbroni M, Cerase A, et al. Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int 2009 Jun; 29(8): 961–5
Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007 Jun; 34(6): 1323–7
Dillon CF, Hirsch R, Rasch EK, et al. Symptomatic hand osteoarthritis in the United States: prevalence and functional impairment estimates from the third U.S. National Health and Nutrition Examination Survey, 1991–1994. Am J Phys Med Rehabil 2007 Jan; 86(1): 12–21
Acknowledgements
The author has received research grants from Novartis and Ferring; consulting fees from Endo, Novartis, Ferring and Rottapharma; and participated in speaker’s bureaus for Ferring and Forest. Jeffrey Coleman, MA, and Robert Gatley, MD, of Complete Healthcare Communications, Inc. (Chadds Ford, PA, USA) provided editorial support for this article (literature search, document retrieval, translation, medical writing and copy editing), with funding from Endo Pharmaceuticals Inc. (Chadds Ford, PA, USA). Endo Pharmaceuticals made no contribution to the content of this manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Altman, R.D. Pharmacological Therapies for Osteoarthritis of the Hand. Drugs Aging 27, 729–745 (2010). https://doi.org/10.2165/11539010-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11539010-000000000-00000